Zelgen Pharmaceutical ZGGS15 bispecific antibody received FDA clinical trial approval
On June 8, 2023, Zelgen Pharma announced that its investigational product ZGGS15 (LAG-3/TIGIT) bispecific antibody clinical trial application has been approved by the US Food and Drug Administration (FDA) for the treatment of advanced solid tumors. According to the public information query, ZGGS15 is the world's first anti-LAG-3 /TIGIT bispecific antibody approved and is about to enter clinical trials.
Previously, on April 24, 2023, Zelgen Pharma announced that the clinical trial of ZGGS15 for injection in the treatment of advanced solid tumors had been approved by the National Food and Drug Administration (NMPA). ZGGS15 for injection has been approved for clinical trials in China and the United States at the same time. Zelgen Pharmaceutical will actively promote the clinical research of this product.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-10-15
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
$161 million! China Biopharmaceutical completes acquisition of F-star Therapeutics
-
Wanhua Chemical Raises Southeast Asia MDI and TDI Offers by $200 per Tonne
-
Ukraine Strikes Russia’s Ryazan Refinery Again, Setting 17-Million-Tonne Facility Ablaze
-
European Petrochemical Weakness Leaves Naphtha Oversupplied as Cracker Demand Struggles
-
Wanhua Chemical’s 2025 Revenue Exceeds RMB 200 Billion While Net Profit Remains Under Pressure
-
“Deregulation” or “Concession”? The Hidden Crisis Behind India’s Repeal of QCOs on Seven Key Petrochemicals
-
MDI Price Surge Hits EMEAI: Is This a Market Correction or the Beginning of a Supply Crisis?
-
Two Saudi Crude Supertankers Hit in Hormuz as Brent Surges to Nearly $95
-
EU Officially Approves Rapeseed Oil as a Low-Risk Active Substance Until 2040
-
EFSA Unable to Confirm Safety of Fusarium flavolapis Fungal Protein as a Novel Food
Recommend Reading
-
![EFSA Confirms Safety of β-Amylase Produced from Barley for Food Manufacturing Use]()
EFSA Confirms Safety of β-Amylase Produced from Barley for Food Manufacturing Use
-
![EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food]()
EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food
-
![Brazil Confirms 32 Methanol Poisoning Cases Linked to Contaminated Alcoholic Beverages]()
Brazil Confirms 32 Methanol Poisoning Cases Linked to Contaminated Alcoholic Beverages
-
![India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence]()
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
![New York’s Additive Ban Signals a Tougher Era for Food Formulation]()
New York’s Additive Ban Signals a Tougher Era for Food Formulation
-
![U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List]()
U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List
-
![Crude Oil + Maintenance Boosts PTA Prices to Rise Amidst Volatility in July]()
Crude Oil + Maintenance Boosts PTA Prices to Rise Amidst Volatility in July
-
![In July, the Chinese anhydrous hydrogen fluoride market showed an upward trend]()
In July, the Chinese anhydrous hydrogen fluoride market showed an upward trend
-
![Business Society September 22, 2026 Palm Oil Trend Analysis: Volatility]()
Business Society September 22, 2026 Palm Oil Trend Analysis: Volatility
-
![Both Costs and Supply-Demand Weaken, PTA Prices Edge Lower]()
Both Costs and Supply-Demand Weaken, PTA Prices Edge Lower
